  
TITLE PAGE  
A SINGLE -ARM, OPEN LABEL CLINICAL STUDY TO COLLECT SAFETY 
DATA ON THE OSTEO PROBE SYSTEM WHEN USED AS A 
MEASUREMENT TOOL 
 
 
Protocol Number:  OP2020  
Version: 4.0 
Date: 21-SEP -2020  
 
 
 
Sponsor:  
Active Life Scientific, Inc.  
[ADDRESS_638668], Santa Barbara, CA [ZIP_CODE]  
Phone:  [PHONE_6271]  
Fax (Optional) : [PHONE_10322]  
 
Sponsor Contact:  
[INVESTIGATOR_124]. Peter Burks  
Chief Executive Officer  
Email:  [EMAIL_9496]  
Phone:  [PHONE_6271] x106  
  
 
 
 
 
 
 
 
 
 
 
This document contains confidential information for use only by [CONTACT_10670] s participating in the clinical 
investigation. This document  should be maintained in a secure location and should not be copi[INVESTIGATOR_496785].  
Clinical Study Protocol  
 
ii 
REVISION HISTORY  
 
Version  Date  Summary of Changes  
1.0 07-MAY -2020  Original Version  
2.0 17-JUL-2020  • Update protocol version number and date on title page , footer,  
Protocol Approval Page  and Investigator Protocol 
Signature [CONTACT_3490].  
• Revise List of Abbreviations  to add BMSi . 
• Revise section [ADDRESS_638669] changes ma de in the body of the protocol and 
add the name [CONTACT_496823].  
• Revise section 3.7 Device Traceabili ty to include detailed 
information on tip assembly labeling and device accountability.  
• Revise section 3.8 Supply and Accountability of 
Investigational Devices  to indicate that device storage 
instructions are documented in the User Guide.  
• Revise section 4.[ADDRESS_638670] the 
number of peer reviewed articles from 41 to 40.  
• Revise section 4.[ADDRESS_638671] 
IDs will be used to mitigate risk.  
• Revise section 4.3 Anticipated Benefits to make it clear that 
there are no anticipated benefits to study subjects  
• Revise secti on 4.4 Risk to Benefit Ratio  to indicate that the 
Investigator will be trained on the protocol.  
• Revise section 5.2 Secondary Objectives  to indicate that 
safety events will be characterized.  
• Revise section 6.1 Study Duration to specify that A Es will be 
followed until no further resolution is expected.  
• Revise section 7.4 Exclusion Criteria  to add clarity to existing 
exclusions, specify exactly how conditions such as allergies and 
infections will be determined and documented, specify that only 
topi[INVESTIGATOR_496786], 
specify that only infections at the procedure site are 
exclusionary and exclude patients with needle phobia and 
additional conditions listed in exclusion criteria #14  
• Revise section 7.6 Informed Consent  to refer to IRB 
guidelines.  
• Revise section 7.8 Screen Failures  to indicate that Screen 
Failures will be captured on a log and re -screens require 
sponsor approval.  
• Revise sections 7.[ADDRESS_638672] Enrollment and 7.11 Treated 
Subjects to clarify when patients are co nsidered enrolled and 
treated and that treated subjects will be followed for 30 days.  
• Revise section [ADDRESS_638673] vitals to be captured, allow for screening procedures 
to be completed over a seven day period, an d specify that 
Clinical Study Protocol  
 
iii 
follow ups may be in person or over video (telehealth) with body 
temperature measurements to help detect possible infections.  
• Revise section 9 Description of Study Procedures  to clarify 
how the medical history will be captured, specify the v itals to be 
captured and document how pregnancy will be evaluated and 
tested.  
• Revise section 10.[ADDRESS_638674] Withdrawals  to clarify that 
patients who withdraw consent prior to treatment will be 
considered screen failures.  
• Revise section 14.1 Definitions  to add the definition of a device 
deficiency and revise the definition of an SAE to match FDA’s 
definition,  
• Revise section 14.2.2 Relationship  to provide detail on how AE 
relationship to the investigational device will be determined.  
• Revise se ction 14.3 AE Reporting Procedures  to clarify when 
AE collection begins and requirements for AE reporting, study 
termination and updating AE status.  
• Revise section 14.4 Treatment of A Es to clarify that A Es will be 
followed until resolved or no further impr ovement is expected.  
• Revise section 14.5 Clinical Events Committee  to clarify the 
role of the CEC.  
•  Revise section 15 Study Monitoring  to include the name [CONTACT_496824].  
• Revise section [ADDRESS_638675] all accurate regulatory requirements.  
• Revise section 18.4 Insurance  to clarify who is insured and 
what they are insured for.  
• Revise section 19.[ADDRESS_638676] Keepi[INVESTIGATOR_496787].  
• Revise section 19.[ADDRESS_638677] Kee pi[INVESTIGATOR_496788].  
• Revise section 19.4 Publication and Data Sharing Policy  to 
indicate that the study will be registered on clinicaltrials.gov and 
results posted.  
• Minor  administrative changes in volving grammar, wordsmithing, 
punctuation, page numbers and other editorial changes have 
been made throughout the document. All are clearly identified in 
the track -changes version of the amendment.  
 
3.0 08-SEP-2020  • Revise sections 1, 1.1, 7.4, 8 and 9 to add x -rays for screening 
and adverse event evaluation.  
• Revise section 7.[ADDRESS_638678] IDs are not generated by 
[CONTACT_14882]  
• Revise section 7.10 and 14.3.1 to clarify the point of enrollment  
4,0 21-SEP-2020  • Revise section 3.[ADDRESS_638679] how Tip Assemblies will be tracked.  
• Make administrativ e change to footer to fix page numbering  
• Add section (New section 15) to describe st udy source 
documentation  
Clinical Study Protocol  
 
iv 
PROTOCOL APPROVAL  SIGNATURE [CONTACT_118258]: OP2020  
 
Protocol Name: A Single -arm, Open Label Clinical Study to Collect Safety Data on the OsteoProbe 
System when used as a Measurement Tool  
 
Protocol Version: 4.0 
 
Protocol Date: 21-SEP-2020  
 
 
This protocol has been read and approved by:  
 
[INVESTIGATOR_206768]:  
 
 
 
 
   
Peter Burks  
CEO  
Active Life Scientific, Inc.   Date (dd/ mmm/yyyy ) 
 
   
CRO:  
 
 
 
 
   
Iman Ahmad  
Director , Clinical Affairs  
MCRA, LLC   Date (dd/mmm/yyyy)  
 
 
 
 
   
Dave McGurl  
Director , Regulatory Affairs  
MCRA, LLC   Date (dd/mmm/yyyy)  
 
 
 
 
 
   
Chris Lotter  
Sr. Director , Data Management & Biostatistics  
MCRA, LLC   Date (dd/mmm/yyyy)  
Clinical Study Protocol  
 
v 
INVESTIGATOR  PROTOCOL SIGNATURE [CONTACT_1783]  
 
I have read and understand this protocol and will conduct the study in accordance with this protocol, all 
attachments and amendments, applicable Food and Drug Administration regulations, HIPAA, IRB 
requirements, and the policies of the institutions where t he study will take place.  
 
In my formal capacity as Investigator, my duties include ensuring the safety of the study subjects enrolled 
under my supervision and providing  Active Life Scientific, Inc.  with complete and timely information, as 
outlined in the protocol.  It is understood that all information pertaining to the study will be held strictly 
confidential and that this confidentiality requirement applies to all study staff at this site.  
 
Protoco l Number:  OP2020  
 
Protocol Title: A Single -arm, Open Label Clinical Study to Collect Safety Data on the OsteoProbe System 
when used as a Measurement Tool  
 
Protoco l Version:  4.0 
 
Protoc ol Date:  21-SEP-2020 
 
 
 
Investigator:  
 
   
(Print Name)    
   
(Signature)  Date (dd/mmm/yyyy ) 
 
 
 
 
Upon signing, send a copy of this page to activelife @mcra.com .com  and retain a copy for your files.  
Clinical Study Protocol  
 
vi 
TABLE OF CONTENTS  
 
TITLE PAGE  ................................ ................................ ................................ ................................ ............  i 
PROTOCOL APPROVAL  SIGNATURE [CONTACT_1783] ................................ ................................ ........................  iv 
INVESTIGATOR  PROTOCOL SIGNATURE [CONTACT_1783]  ................................ ................................ .................  v 
LIST OF ABBREVIATIONS  ................................ ................................ ................................ .....................  1 
1. Study Sum mary  ................................ ................................ ................................ ................................  2 
1.1 Schedule of Events  ................................ ................................ ................................ ..................  5 
2. Introduction  ................................ ................................ ................................ ................................ ...... 6 
2.1 Background  ................................ ................................ ................................ ..............................  6 
2.1.1 OsteoProbe® System  ................................ ................................ ................................ ...........  6 
2.1.2 Diagnosis and Current Treatment Options  ................................ ................................ ............  6 
3. Investigational Device  ................................ ................................ ................................ .......................  6 
3.1 Investigational Device Overview  ................................ ................................ ...............................  6 
3.1.1 Technological Characteristics  ................................ ................................ ...............................  7 
3.2 OsteoProbe Device Component Description  ................................ ................................ .............  8 
3.2.1 Tip Assembly  ................................ ................................ ................................ ........................  8 
3.2.2 Stylus  ................................ ................................ ................................ ................................ ... 8 
3.2.3 Holder & Reference Materials  ................................ ................................ ...............................  8 
3.2.4 Power Controller (Electronics)  ................................ ................................ ..............................  9 
3.2.5 Operator Interface  ................................ ................................ ................................ ................  9 
3.3 Technical Specifications  ................................ ................................ ................................ .........  10 
3.4 Device Sterilization  ................................ ................................ ................................ .................  11 
3.5 Device Packaging and Labeling  ................................ ................................ ..............................  11 
3.6 Indications for Use ................................ ................................ ................................ ..................  11 
3.7 Device Traceability  ................................ ................................ ................................ .................  12 
3.8 Supply and Accountability of Investigational Devices  ................................ ..............................  12 
3.9 Device Use Experience and Training  ................................ ................................ ......................  12 
4. Benefit -Risk Analysis  ................................ ................................ ................................ ......................  12 
4.1 Risks  ................................ ................................ ................................ ................................ ...... 13 
4.2 Risk Mitigation  ................................ ................................ ................................ ........................  13 
4.3 Anticipated Benefits  ................................ ................................ ................................ ................  14 
4.4 Risk-to-Benefit Ratio  ................................ ................................ ................................ ..............  14 
5. Study Objectives ................................ ................................ ................................ .............................  14 
5.1 Primary Objectives  ................................ ................................ ................................ .................  14 
5.2 Secondary Objectives ................................ ................................ ................................ .............  14 
6. Study Design  ................................ ................................ ................................ ................................ .. 15 
6.1 Study Duration  ................................ ................................ ................................ .......................  15 
Clinical Study Protocol  
 
vii 
6.2 Treatment/Control Group  ................................ ................................ ................................ ........  15 
6.3 Primary Endpoints  ................................ ................................ ................................ ..................  15 
6.4 Secondary Endpoints  ................................ ................................ ................................ .............  15 
6.5 Treatment/Control Groups and Blinding  ................................ ................................ ..................  [ADDRESS_638680] Enrollment  ................................ ................................ ................................ .................  18 
7.11 Treated Subjects  ................................ ................................ ................................ ....................  18 
8. Study Vis it Procedures ................................ ................................ ................................ ....................  18 
8.1 Visit 1:  Screening/Procedure Visit  ................................ ................................ ..........................  18 
8.2 Visit 2: 1 -Day Follow -Up (+2 days) ................................ ................................ ..........................  19 
8.3 Visit 3: 7 -Day Follow -Up (± 3 days)  ................................ ................................ .........................  19 
8.4 Visit 4: 30 -Day Follow -Up (± 10 days)  ................................ ................................ .....................  20 
8.5 Out Of Window and Missed Visits  ................................ ................................ ...........................  20 
8.6 Unscheduled Visits  ................................ ................................ ................................ .................  20 
8.7 Study Completion/Discontinuation  ................................ ................................ ..........................  [ADDRESS_638681] to Follow -Up (LTFU)  ................................ ................................ ................................ ....... [ADDRESS_638682] Withdrawals  ................................ ................................ ................................ ...............  22 
10.3 Documentation of Early Discontinuation ................................ ................................ ..................  22 
10.4 Use of Data from Early Discontinuation Cases  ................................ ................................ ........  23 
10.5 Ongoing Treatment for Early Discontinuation Cases  ................................ ...............................  23 
11. Early Discontinuation: Study  ................................ ................................ ................................ ....... [ADDRESS_638683] (UADE)  .....................  27 
14.4 Treatment of AEs  ................................ ................................ ................................ ...................  27 
14.5 Clinical Events Committee (CEC)  ................................ ................................ ...........................  27 
15. Study Monitoring  ................................ ................................ ................................ ........................  28 
15.1 Site Mo nitoring  ................................ ................................ ................................ .......................  28 
15.2 Monitoring Activities  ................................ ................................ ................................ ...............  28 
15.3 Frequency of Visits  ................................ ................................ ................................ .................  29 
16. Audits and Inspections  ................................ ................................ ................................ ...............  29 
17. Statistical Analysis Plan  ................................ ................................ ................................ .............  30 
17.1 Study Hypothesis  ................................ ................................ ................................ ...................  30 
17.2 Sample Size Analysis  ................................ ................................ ................................ .............  30 
17.3 Study Populations  ................................ ................................ ................................ ..................  32 
17.3.1  Primary Analysis Set  ................................ ................................ ................................ ....... 32 
17.3.2  Per Protocol Analysis Set  ................................ ................................ ...............................  32 
17.3.3  Training Cases  ................................ ................................ ................................ ...............  32 
17.4 Testing  of Primary Safety Hypotheses  ................................ ................................ ....................  32 
17.5 Missing Data/Sensitivity Analysis  ................................ ................................ ............................  [ADDRESS_638684] follow -up visit.  
• 2 months enrollment period (estimation)  
• [ADDRESS_638685]  will be evaluated  at: 
• Screening/Procedure  
• 1-Day (+2 days ) 
• 7-Day ((±3 days ) 
• 30-Day (±10 days ) 
ELIGIBILITY CRITERIA  
Intended Subject Population  A total of [ADDRESS_638686] 
meet all of the following inclusion criteria:  
 
1. Be greater than or equal to 22 years of age ; 
2. Be able to give voluntary, written informed consent to 
participate and have signed an Informed Consent Form 
specific to this study  
3. If female and of child -bearing potential, must have a 
negative pregnancy status . 
Main Exclusion Criteria  Subjects who meet any of the following criteria will be excluded 
from participating in this study:  
 
1. Active skin infection at the procedure site as identified 
during a SOC physical examination.  
2. Subject -reported or known systemic infection;  
3. Subject -reported or known allergy to l ocal anesthetic;  
4. Subject -reported or known allergy to stainless steel or 
nickel materials;  
5. Subject -reported or known current use of systemic 
antibiotics, or topi[INVESTIGATOR_496789] ; 
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, [ADDRESS_638687] -reported or known history of needle  phobia;  
7. Significant soft tissue at the procedure site which would 
preclude use of the OsteoProbe in the judgement of the 
Investigator;  
8. Known instance of hardware in the tibia that is intended to 
be measured  based on radiographic imaging ; 
9. Known instance of  a previous or current fracture in the tibia 
that is intended to be measured  based on radiographic 
imaging ; 
10. Are known to be actively participating or known to have 
participated in a nother  clinical investigation for which they 
received an investigational product (including but not 
limited to a drug or vaccine) within the last 90 days, or 
reports that they intend to participate in another clinical 
investigation during the course of the study;  
11. Are known to be curren tly abusing drugs or alcohol or have 
a known history of the same within the last 12 months;  
12. Have any known or subject reported mental or 
psychological disorders that, in the judgement of the 
Investigator, would impair their ability to accurately 
complete the NRS Pain Score survey s; 
13. Are currently a prisoner;  
14. Have a condition which, in the judgemen t of the 
Investigator, would preclude adequate evaluation of the 
device’s safety and performance. Conditions include but 
are not limited to:  
a) Regional or systemic pain syndromes  
b) Radicular pain syndromes  
c) Chronic or intermittent leg pain  
d) Migraine headaches   
 
STUDY ENDPOINTS  
Primary Endpoint  The incidence of device -related serious adverse events (SAEs)  in 
subjects evaluated with the OsteoProbe System.  
Secondary Endpoints  The secondary endpoints of this study, following  evaluation with the 
OsteoProbe System , are:  
1. NRS Pain scores at Procedure , 1-day, 7-day and 30 -day 
follow up visits ; 
2. BMSi  scores after the OsteoProbe  procedure ; 
3. Adverse event rates through Day 30; 
4. Device -related adverse events through Day 30; 
5. Serious adverse events through Day 30; and  
6. Unanticipated adverse device effects (UADE) through Day 
30. 
STATISTICAL CONSIDERATIONS  
Sample Size  40 IDE Subjects  
 
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, 21 SEP 2020   
      Page 4 of 37 
A literature review was performed by [CONTACT_496796]. 
These six studies contain 215 subjects with zero subjects 
experiencing device -related  serious adverse events. Given there is 
no variability between these studies, the data are pooled together 
and collectively constitute the informative prior. The informative 
prior was constructed as Jeffries prior plus the data  from the 
literature , that is, Beta(.5 + data, .5 + data).  
When there are zero device -related  SAEs in [ADDRESS_638688] been shown to meet the performance goal. Therefore, only if 
there are zero device -related  SAE’s will the alternative hypothesis 
be accepted.  
Statistical Plan  The primary hypothesis is that the probability of experiencing 
device -related  Serious Adverse Events (SAE) for subjects treated 
with the investigational device is smaller than the performance goal 
of 1%. Formally, the hypothesis to be tested is: 
H0: The expected proportion of subject s with device -related  SAE up 
to Day 30 (p T) is gr eater than or equal to the performance goal (PG) 
of 1.0%.  
HA: The expected proportion of subject s with device -related  SAE up 
to Day 30 (p T) is less than the performance goal (PG) of 1.0%.  
These hypotheses may be symbolically represented as:  
H0: pT ≥ PG = 1 .0% 
Ha: pT < PG = 1.0%  
Where p T is the device -related  SAE rate for subjects treated with 
the investigational device.  
If the Bayesian Posterior Probability that pT < PG is greater than or 
equal to .975, the alternative hypothesis will be accepted, and it wi ll 
be concluded that the device meets the performance goal.  
 
STUDY MANAGEMENT   
Principal Investigator  [INVESTIGATOR_496790], LLC,  
[ADDRESS_638689], Omaha, Nebraska [ZIP_CODE]  
Clinical Research Organization 
(CRO)  MCRA , LLC 
[ADDRESS_638690] NW, Suite 1000  
Washington DC [ZIP_CODE]  
 
  
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, 21 SEP 2020   
      Page 5 of 37 
1.1 SCHEDULE OF EVENTS  
 
Activity  Visit 1  
Screening/
Procedure1 Visit 2  
1-Day2,3 
(+ 2 days)  Visit 3  
7-Day2,3 
(±3 days)  Visit 4  
30-Day2 
(±10 days)  Unscheduled  
Informed Consent  X - - - - 
Inclusion/Exclusion Criteria  Review  X - - - - 
Demographics  X - - - - 
Medical History  X - - - - 
Physical Examination ( including  vitals ) X - - - - 
X-Rays (AP & Lateral)  X - - - - 
Pregnancy Evaluation/ Test4 X - - - - 
OsteoProbe Test Procedure  X - - - - 
NRS Pain  Score  X5 X X X X 
Record BMSi  Score  X - - - - 
Body Temperature   X X X X 
Record/Review Concomitant Medications  X X X X X 
Record/Review Adverse Events  X6 X6 X6 X6 X6 
Record/Review Device Deficiencies  X - - - - 
Work status  X X X X X 
1 The Screening/Proce dure visit m ay take  place over multiple days , but the OsteoProbe procedure must be completed 
within 7 days of signing the ICF.  
2 To be conducted as telehealth visits with video interviews; option of in -person visits is acceptable if th at is preferred by 
a subject or the Investigator.  
[ADDRESS_638691] be completed once prior to the OsteoProbe procedure (baseline) and again following completion 
of the procedur e. 
6 X-rays will be ordered by [CONTACT_496797] a potential tibial fracture 
based on clinical exam and/or adverse event details provided by [CONTACT_423].  
 
 
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, 21 SEP 2020   
      Page 6 of 37 
2. INTRODUCTION  
2.1 BACKGROUND  
2.1.1  OsteoProbe®  System   
The OsteoProbe®  System  (“OsteoProbe”)  is a bone microindentation measurement tool.  
 
2.1.2  Diagnosis and Current Treatment Options  
The device is a measurement tool that is not intended to make a diagnosis or provide a treatment decision.  
There  are no other available measurement tools for clinical assessment of bone’s resistance to 
microindentation.  
 
3. INVESTIGATIONAL DEVICE  
3.1 INVESTIGATIONAL DEVICE OVERVIEW  
OsteoProbe  is a bone microindentation measurement tool.  It is intended  to measure bone tissu e’s resistance 
to microindentation on the left or right tibia in adults.  It is a prescription device per 21 CFR Part 801.109 . The 
device  consists of five (5) components: 1) Styl us, 2) Power Controller (Electronics), 3) Holder  and Reference 
Materials , 4) Ti p Assembly , and 5) Operator Interface ( Figure 1). The OsteoProbe  includes a single -use 
disposable component  (Tip Assembly)  and reusable components  (Stylus, Power Controller, and Holder) .  
 
Figure 1: OsteoProbe Device  
 
 

Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, 21 SEP 2020   
      Page 7 of 37 
Table 1: OsteoProbe Device Components  
Component  Part 
Number  Component  Representative Image  
1 OPA -900 Stylus  
 
2 OPB -900 Power Controller 
(Electronics ) 
 
3 OPC -900 Holder  and Reference 
Materials  
 
4 OPD -900 Tip Assembly  
 
5 OPH -900 Operator Interface  N/A 
 
3.1.[ADDRESS_638692] material (i. e., bone) with a known force. Traditional microindentation testing has 
specific ASTM defined methods for calculating mechanical properties, like hardness. ASTM defined methods 
use specific shape indenters and measure indentation depth to calculate an arbit rary hardness number (e.g. 
Rockwell, Vickers). OsteoProbe operates according to the same principles and calculates a unique 
parameter: resistance to microindentation. The system software reports a simple numerical score with no 
reference to clinical utilit y or other information regarding the health status of the subject . 
 

Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, 21 SEP 2020   
      Page 8 of 37 
3.2 OSTEOPROBE DEVICE COMPONENT DESCRIPTION  
3.2.1  Tip Assembly  
The Tip Assembly  is attached to the Stylus in order to perform a measurement. The Tip Assembly is 
composed of two sub -components, the T ip and a Guide  (Figure 2). The Guide retains the Tip and seals via a 
luer lock fitting to the Stylus. The Tip Assembly is the only component that directly contacts the subject . 
 
 
Figure 2: OsteoProbe Tip Assembly  
 
 
The Tip Assembly component is single -use and disposable. The Tip Assembly is  packaged and  shipped 
non-sterile. Sterilization instructions are provided to the end user.  
 
3.2.2  Stylus  
The Stylus  component  consists of an outer Handle and an internal Body  (Figure 3). The Stylus contains an 
actuation mechanism and sensor that measures the indentation depth of a Tip.  
Figure 3: OsteoProbe Stylus  
 
3.2.3  Holder & Reference Materials  
The Holder consists of an enclosure/box that secures Reference Materi als. There are two Reference 
Materials. The Reference Block, which is made from polymethylmethacrylate, is used after each 
measurement on a subject  and is discarded after use. The Performance Check Block, which is made from 
epoxy resin (aka Noryl), is util ized during performance checks. These periodic verifications only ensure 
system is functioning as expected and are not used to calibrate the device. Both blocks are 1” x 1” x 0. 5” (L x 
W x H) and are disposed of after a single use.  
Figure 4: OsteoProbe Holder  
 
 
Tip Guide  
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, 21 SEP 2020   
      Page 9 of 37 
Specifications of the OsteoProbe Holder and Reference Materials are summarized in Table 2 below.  
Table 2: OsteoProbe Holder and Reference Materials  Specifications  
Parameter  Value  
Reproducibility  Reference Block : 
Performance Check Block:  ± 1%  
± 1%  
Dimensions  Reference Block : 
Performance Check Block:  
Holder:  1” x 1” x 0.5”  
1” x 1” x 0.5”  
3.5” x 3.5” x 1.6”  
Weight  Holder:  5 lb 
 
3.2.4  Power Controller (Electronics)  
The Power Controller consists of electronics  that provide power and  convert the analog signal from the 
Stylus into a digital signal which is processed  by [CONTACT_496798] . No pr ocessing 
takes place in the power controller.  
Figure 5: OsteoProbe Power Controller (Electronics)  
 
 
Specifications of the OsteoProbe Power Controller are summarized in Table 3 below.  
Table 3: OsteoProbe Stylus Specifications  
Parameter  Value  
Power Input Requirements  Voltage:  
Frequency:  
Current:  100 – 240 V~  
50 – 60 Hz  
1.5 A  
Case Dimensions  Approximately:  46 x 34 x 17 cm 
Case Weight  Approximately:  8 kg 
Transport Conditions  Ambient Temperature:  
Relative Humidity:  
Atmospheric Pressure:  -20°C to 50°C  
10% to 90%, non -condensing  
28k Pa to 110 kPa  
Operating & Storage Conditions  Ambient Temperature:  
Relative Humidity:  
Atmospheric Pressure:  10°C to 30°C  
20% to 80%, non -condensing  
71 kPa to 101 kPa  
 
3.2.5  Operator Interface  
The OsteoProbe Power Controller interfaces with a personal computer terminal via a USB port . The 
OsteoProbe Operator Interface consists of a software program that runs on a Windows 10 operating system 

Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, 21 SEP 2020   
      Page 10 of 37 
and processes the digital signal sent by [CONTACT_496799]. The Operator Interface provides the user 
control of the OsteoProbe to initiate a measurement. The Operator Interface will then store and display the 
measurement data as a simple numerical score.  
Figure 6: OsteoProbe Operato r Interface Running on a Laptop  
  
 
Specifications of the OsteoProbe Operator Interface and Personal Computer specifications  are summarized 
in Table 4 below.  
Table 4: OsteoProbe Operator Interface and Personal Computer  Specifications  
Parameter  Value  
Internet Connectivity  Wireless:  
Ethernet:  802.11b/g/n  
RJ-45 (100/1000 Mbps)  
Operating System  Windows 10 Professional   
Interface Port  USB A   
 
3.3 TECHNICAL SPECIFICATIONS  
A summary of the system technical specifications is provided below ( Table 5). 
Table 5: OsteoProbe General Technical Specifications  
Parameter  Parameter Value  
System Classification  FDA Class  CAUTION: limited by [CONTACT_496800].  
EU Class  Class IIa  
Safety Certifications  U.S.A. Certification  IEC [ZIP_CODE] -1: 2012  
EU Certification  IEC [ZIP_CODE] -1: 2012  
EMC Certifications  IEC [ZIP_CODE] -1-2:2014, Medical electrical equipment – Part 1 -2: 
General requirements for basic safety and essential performance - 

Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, [ADDRESS_638693]: Electromagnetic compatibility – Requirements 
and tests  
• CISPR 11:2015+A1:2016 - Limits and methods of measu rement 
of radio disturbance, Characteristics of industrial, scientific and 
medical radio frequency equipment  
• IEC [ZIP_CODE] -4-2:2008 - Electromagnetic Compatibility -Part 4: 
Testing and measurement techniques – Section 2: Electrostatic 
discharge immunity test  
• IEC [ZIP_CODE] -4-3:2010 - Electromagnetic Compatibility -Part 4: 
Testing and measurement techniques – Section 3: Radiated, 
radio -frequency, electromagnetic field immunity test  
• IEC [ZIP_CODE] -4-4:2012 - Electromagnetic Compatibility -Part 4: 
Testing and measurement  techniques – Section 4: Electrical fast 
transient/burst immunity test  
• IEC [ZIP_CODE] -4-5:2005 - Electromagnetic Compatibility -Part 4: 
Testing and measurement techniques – Section 5: Surge 
immunity test  
• IEC [ZIP_CODE] -4-6:2013 - Electromagnetic Compatibility -Part 4: 
Testing and measurement techniques – Section 6: Conducted 
immunity test  
• IEC [ZIP_CODE] -4-8:2009 - Electromagnetic Compatibility -Part 4: 
Testing and measurement techniques – Section 8: Power 
frequency magnetic field immunity test  
• IEC [ZIP_CODE] -4-11:2004 - Electromagnetic Compatibility -Part 4: 
Testing and measurement techniques – Section 11: Voltage dips 
and interruptions immunity test  
IEC [ZIP_CODE] -3-2:2014 - Electromagnetic compatibility (EMC) -Part 
3-2: Limits - Limits for harmonic current emissions (equipment  
input current < 16A per phase)  
IEC [ZIP_CODE] -3-3:2013 - Electromagnetic compatibility (EMC) -Part 
3-3: Limits – Limitation of voltage changes, voltage fluctuations 
and flicker in public low -voltage supply systems, for equipment 
with rated current < 16A per ph ase and not subject to conditional 
connection  
CE Marking  CE Marking for MDD 93/42/EEC  
 
3.[ADDRESS_638694] be reprocessed (cleaned and 
intermediate level disinfected) between each use.  
 
3.5 DEVICE PACKAGING AND LABELING  
Device packaging and labeling are described in the User Manual.  
 
3.6 INDICATIONS FOR USE  
The OsteoProbe System is indicated for use as a measurement tool to measure bone tissue’s resistance to 
microindentation on the left or right tibia in adults.  It is not intended to make a clinical diagnosis.  
 
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, [ADDRESS_638695] within the 
Company quality management system. The Tip Assembly of the device  is single -use and disposable. The 
Tip Assembly components  (tip and guide)  are no t individually  serialized .  Unique  Tip-ID labels are provided  
which a re affixed to each sterilization pouch allowing for accountability of each Tip Assembly and traceability 
to manufactured lot.  
 
All devices will be shipped via commercial shipper with a tracking number.  
 
3.[ADDRESS_638696] used in this study will be consistent with 21 CFR Part 821 and ISO 
[ZIP_CODE]:2011, and in a ccordance with local regulations. Devices will be stored in a secure location at the 
investigational site  per the specifications in the User Manual which is only accessible to the Investigator  and 
delegated site staff.  OsteoProbe devices, labeled for Inves tigational Use Only, will be shipped directly to the 
clinical study site from: Active Life Scientific, Inc . 
 
The Investigator  or delegate  will maintain a Device Accountability Log to document the date of receipt, Tip 
ID, date of  use, and final disposition of each device and Assembly Tip  that they utilize  during the course of 
the study. The log will be filed in the site’s ISF and will be available for review during monitoring visits.  
 
3.[ADDRESS_638697] of published literature can be found in  the Report of Prior Investigations.  
 
Active Life Scientific, Inc.  has implemented a risk management process in conformance with  EN ISO [ZIP_CODE]. 
This risk management process includes risk management plan, risk analysis, risk evaluation, and risk 
control. The application of this risk management process is documented in a risk management file with a risk 
management plan. Documentation for the OsteoProbe  risk management file will include:  
 
• OsteoProbe device -related risks  
• Clinical risks  
• Risk mitigation  
• Anticipated clinical benefits  
• Risk-to-benefit rationale  
• Conclusions from pre -clinical risk evaluation and justification for clinical investigation.  
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, 21 SEP 2020   
      Page 13 of 37 
4.1 RISKS  
The potential device - and procedure -related risks  associated with the OsteoProbe dev ice were identified as : 
• Allergic reaction to anesthetic or device materials  
• Mechanical failure or breakage of device  
• Discomfort  
• Pain 
• Bruising  
• Bleeding  
• Soft tissue infection  
• Bone infection  
• Bone fracture  
The probability of risks associated with the use of the OsteoProbe device are expected to be low. All adverse 
events will be captured and assessed by [CONTACT_737] .  
 
The subjects in t his study will be exposed to the potential risks associated with the OsteoProbe device. 
There is clinical data on the device which help to understand that the risks associated with participation in 
the study to be relatively low.   
 
Trial-specific risks in clude the risks associated with study -related assessments , data collection and loss of 
confidentiality.  
 
Clinical investigations performed in this trial include non -invasive clinical evaluations and interview 
questionnaires. Questionnaires applied to this investigation are standard research instruments and have 
been applied in a large number of studies.  
 
As a result of participating in the study, there could be a risk of loss of protected subject information 
confidentiality.  
4.[ADDRESS_638698] been or will be 
minimized.  
• Study Design  
• Subject  monitoring  
• Subject  selection  
• Anonymization of subjects’ identities via the use of Subject IDs on all study records  
• Device design  
• Procedure Guide  & User Manual  
• Operator training  
• Mechanical testing  
• Software Validation  
• Cybersecurity  
• Sterilization and Cleaning Validation  
• Electrical Safety and EMC  
• Biocompatibility  
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, [ADDRESS_638699] been mitigated or minimized 
through design, labeling, training and validation/verification according to ISO [ZIP_CODE].  
 
4.[ADDRESS_638700] the safety of the 
OsteoProbe®, the potential benefits would be for patients in the future.  
 
4.4 RISK -TO-BENEFIT RATIO  
Based on the potential benefits liste d above, and the anticipated risks, Active Life Scientific believes this 
study is justified for the following reasons:  
• OsteoProbe device is designed and constructed based on the principles of performing a 
measurement without causing pain or harm to the subject. 
• Robust testing has been performed supporting safety of the OsteoProbe device as designed for its 
intended use.  
• Biocompatibility analyses and material history provide a reasonable assurance of material safety.  
• The clinical protocol is designed to yield valid scientific evidence to support an FDA de novo 
submission.  
• The subject s will be screened and closely monitored for any potential adverse events.  
• The Investigator has been carefully selected and will be trained  on the use of this device and the 
execution of this clinical protocol . 
• Study subjects will be selected according to specific inclusion/exclusion criteria and evaluated 
frequently.  
• The Sponsor will closely monitor the study, and adverse events will be recorded and reported 
promptly to the Sponsor.  
• A Clinical Events Committee (CEC) will be convened to independently review adverse events.  
The risks identified above have been minimized to the furthest extent possible, through pre -clinical bench 
testing, subject  and Investigator  selection, and pr oper labeling. In addition, all subject s will be informed of the 
potential risks during the informed consent  discussion .  
 
Therefore, given the information provided throughout this submission, Active Life Scientific has adequately 
evaluated the safety of t he device and put into place adequate clinical controls to initiate the start of an IDE 
study.  
 
5. STUDY OBJECTIVES  
5.[ADDRESS_638701]  and characterize  safety data associated with the use of the OsteoProbe System . 
 
5.2 SECONDARY OBJECTIVES  
Obtain information on pain regarding the procedure  and characterize all safety events .  
 
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, 21 SEP 2020   
      Page 15 of 37 
6. STUDY DESIGN  
The stud y is a p rospective, single center , open label clinical study. 
 
6.1 STUDY DURATION  
The study is expected to take approximately three (3) months from first subject enrolled to the last follow -up 
visit. 
• 2 month enrollment period (estimation)  
• [ADDRESS_638702] to follo w-up. 
 
6.2 TREATMENT/CONTROL GROUP  
The study will be a single arm study with no control group.  
 
6.3 PRIMARY ENDPOINT S 
The incidence of device -related serious adverse events (SAEs) in subjects evaluated with the OsteoProbe 
System.  
 
6.4 SECONDARY ENDPOINTS  
The secondar y endpoints of this study, following evaluation with the OsteoProbe System, are:  
1. NRS Pain  scores  at Procedure, 1 -day, 7 -day and 30 -day follow up visits ; 
2. BMSi  scores a fter the OsteoProbe  procedure ; 
3. Adverse event  rates through Day 30;  
4. Device -related adverse events through Day 30; 
5. Serious adverse events through Day 30; and  
6. Unanticipated adverse device effects (UADE) through Day 30.  
6.5 TREATMENT/CONTROL GROUPS  AND BLINDING  
A total of forty (40) subjects will be enrolled in a single -arm inves tigational “ OsteoProbe ” group. In this 
investigation, neither the Investigator  nor the subject can be blinded to the investigation  group assignment 
after undergoing the measurement with the investigational device.  
  
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, [ADDRESS_638703] RECRUITMENT  
Subjects participating in this study will be recruited from the Investigator s’ standard patient populations. All 
subject s will be evaluated for study participation based on the inclusion/exclusion criteria listed below.  
Subjects must me et all of the following inclusion criteria and none  of the exclusion criteria. The Investigator  
maintains exclusive responsibility assessing the eligibility of  all potential study participant s. 
 
7.2 NUMBER OF SUBJECTS AND INVESTIGATIONAL SITES  
A total of forty  (40) subject s will be enrolled at a single US site.  
 
7.[ADDRESS_638704] meet all of the following  inclusion  criteria:  
1. Be greater than or equal to 22 years of age;  
2. Be able to give voluntar y, written informed consent to participate and have signed an Informed 
Consent Form specific to this study ; 
3. If female and of child -bearing potential, must have a negative pregnancy status.  
7.4 EXCLUSION CRITERIA  
Subjects who meet any of the following criteria will be excluded from participating in this study:  
1. Active skin infection  at the procedure site as identified during a SOC physical examination . 
2. Subject  reported  or known systemic infection;  
3. Subject  reported or known a llergy to local anesthetic ; 
4. Subject  reported or known a llergy to stainless steel or nickel materials ; 
5. Subject  reported or known  current use of  systemic antibiotics , or topi[INVESTIGATOR_496791];  
6. Subject reported or known history of needle phobia ; 
7. Significant soft tissue at the procedure site which would preclude use of the OsteoProbe  in the 
judgement of the Investigator ; 
8. Known instance of hardware in the tibia that is intended to be measured  based on radiographic 
imaging ; 
9. Known instance of a previous or current fracture in the tibia that is intended to be measured  based 
on radiographic imaging ; 
10. Are known to be actively participating or known to have participated in a nother  clinical investigation  
for which they received an investigational product (including but not limited to a drug or vaccine) 
within the last 90 days, or reports that they intend to participate i n another clinical investigation 
during the course of the study ; 
11. Are known to be currently abusing drugs or alcohol or have a known history of the same within the 
last 12 months ; 
12. Have any known or subject  reported mental or psychological disorder s that, in the judgement of the 
Investigator,  would impair their ability to accurately  complete the  NRS Pain Score survey s; 
13. Are currently a prisoner ; 
14. Have a condition which, in the judgement of the Investigator , would preclude adequate evaluation of 
the device’s safety and performance . Conditions include but are not limited to:  
a) Regional or systemic pain syndromes  
b) Radicular pain syndromes  
c) Chronic or intermittent leg pain  
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, 21 SEP 2020   
      Page 17 of 37 
d) Migraine  headaches  
7.[ADDRESS_638705] in the 
clinical investig ation is discontinued; his/her rights; the applicable damage compensation system and will 
answer any questions that the subject has. The study will be explained to the subject in lay terms and 
adequate time will be allowed for the subject to ask questions.  Interested subjects will be invited to 
participate in the study and will be asked to provide written informed consent prior to initiation of any study -
related procedures. Subjects will be assured that they may withdraw from the study at any time and for a ny 
reason, without repercussion. If the subject agrees to participate, the informed consent form (ICF) must be 
signed and dated by [CONTACT_496801]. The informed consent 
process shall be documented in the subject’ s medical file.  
 
The informed consent form that is used must be approved by [CONTACT_1383]/IRB. A dated and signed copy of the 
informed consent form will be given to the subject and the original dated and signed consent will be placed in 
the subject’s research fi le. 
 
If new information becomes available that can significantly affect a subject's future health and medical care 
that information shall be provided to the subjects affected in written form at. If relevant, all affected subjects 
shall be asked to confirm t heir continuing informed consent in writing.  
 
A signed ICF must be obtained from every subject before any study -related procedures beyond SOC 
are performed.  
 
Failure to obtain a signed and dated informed consent form prior to performing study -related procedures 
constitutes a protocol violation, which must be reported to the IRB in accordance with their reporting 
guidelines . 
 
7.[ADDRESS_638706]’s demographics, medical history, physical 
examination  and current medications and therapi[INVESTIGATOR_014].  
 
7.[ADDRESS_638707]’s signed ICF and completed 
inclusion/exclusion criteria will be retained by [CONTACT_737], and the subject will be notified.  
 
Screening data, including the reason for exclusion, will be collected  but may not be complete in cases where 
the subject is determined to be a screen failure early in the screening process. A record of all screened 
subjects will be maintained in a Screening & Enrollment Log.  The subject’s exclusion from the study and 
reason  for ineligibility will be documented on the Screening & Enrollment Log.  
 
NOTE: If a subject does not meet the eligibility criteria during their Screening Visit , the subject may be re -
evaluated for entry into the study at a later time if deemed appropriate  by [CONTACT_737] . These subjects 
will require formal written Sponsor approval, and the subject will need to be re -consented , sign a new 
informed consent form , and undergo a full review of the inclusion/exclusion criteria by [CONTACT_737] . 
 
7.[ADDRESS_638708] Identification Number will be captured on the Screening & Enrollment Log and 
used to identify them on all source documents and eCRFs thereafter.  
 
7.[ADDRESS_638709] who has had the OsteoProbe measur ement procedure completed  
and a BMSi  measurement was recorded . All treated subjects, including those found to be ineligible after 
enrollment, will be followed for the next 30 days in accordance with the Schedule of Assessments.  
 
8. STUDY VISIT PROCEDURES  
8.1 VISIT 1:  SCREENING /PROCEDURE  VISIT  
Note: The Screening/Procedure visit may take place over multiple days, but the OsteoProbe procedure must 
be completed within [ADDRESS_638710]  
eligibility. The screening will include a documentation of demographics, medical history, physical exam  with 
vitals  (temperature, blood pressure, pulse and respi[INVESTIGATOR_697]),  x-rays to rule out tibial fractures  or implants , 
pregnancy evaluation (for women of childbearing potential only) , work status, and concomitant medications .  
 
Upon successful confirmation of subject eligibility , the subject will undergo the following:  
 
Baseline NRS Survey  
• The subject will comp lete a baseline N umerical Rating Scale (NRS)  Survey right before initiating the 
OsteoProbe test procedure  
 
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, [ADDRESS_638711] Procedure  
• The Investigator will clean the test site and apply a local anesthetic agent prior to perform ing the 
OsteoProbe procedure , as outlined in the Procedure  Guide , with the assigned device . The 
Investigator will note the anesthetic agent used, tim e of delivery and the volume adminis tered in the 
subject’s study records .  
• The procedure  start time will be recorded as the time of first insertion of the Tip to the bone surface  
• The p rocedure  stop time will be recorded as the time the Tip is removed from the skin  following the 
final indenta tion  
• The Investigator  will consider the procedure to be successful once the OsteoProbe software displays 
the B MSi 
• If the Investigator  cannot complete the procedure for any reason, they should stop the use of the 
device on this subject  and treat the subjec t per SOC  
Post -Procedure  (< 60 Minutes)  
• The Investigator or delegate will apply a dressing to the test site per SOC  
• The Investigator or delegate will r ecord the BMSi  Score 
• The subject  will complete the post-procedure Numerical Rating Scale (NRS)  Survey – this pain 
survey must be administered prior to performing any adverse event or device deficiency evaluations  
to prevent information from these assessments biasing the subject’s responses.  
• The Investigator or delegate will r ecord adverse events and device deficiencies, if applicable  
• The Investigator or delegate will r eview the suggested post -procedure  regimen with the subject  per 
the User Manual  
• The Investigator or delegate will perform a r eview of concomitant medications  with the subject  
 
8.2 VISIT 2 : 1-DAY FOLLOW -UP (+2 DAYS)  
To allow the Investigator’s assessment of the subject’s progress, the subject will be contact[CONTACT_496802] a telehealth appointment and interviewed /examined  to assess the following : 
 
• The subject ’s Numerical R ating Scale (NRS)  pain score  – this pain survey must be administered 
prior to performing the other visit assessments to prevent information from these assessments 
biasing the subject’s responses.  
• New or updated adverse events, if applicable  
• Current work st atus  
• Review of concomitant medications  
• Current body temperature ( for telehealth visits, the patient will take their temperature during the visit 
while being observed and display thermometer reading for the Investigator to confirm and record)  
 
8.3 VISIT 3 : 7-DAY FOLLOW -UP (± 3 DAYS) 
To allow the Investigator’s assessment of the subject’s progress, the subject wil l be contact[CONTACT_496802] a telehealth appointment and interviewed /examined  to assess the following:  
 
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, 21 SEP 2020   
      Page 20 of 37 
• Numerical Rating Scale (NRS)  pain score  – this pain survey must be administered prior to 
performing the other visit assessments to prevent in formation from these assessments biasing the 
subject’s responses.  
• New or updated adverse events, if applicable  
• Current work status   
• Review of concomitant medications  
• Current body temperature ( for telehealth visits, the patient will take their temperature during the visit 
while being observed and display thermometer reading for the Investigator to confirm and record)  
 
8.4 VISIT 4 : 30-DAY FOLLOW -UP (± 10 DAYS) 
To allow the Investigator’s assessment of the subject’s progress, the subject will be contact[CONTACT_496802] a telehealth appointment and interviewed /examined  to assess the following:  
 
• Numerical Rating Scale (NRS)  pain score – this pain survey must be administered prior to 
performing the other visit assessments to prevent information from these assessments biasing the 
subject’s responses.  
• New or updated adverse events, if applicable  
• Current work status   
• Review of concomitant medications  
• Current b ody temperature ( for telehealth visits, the patient will take their temperature during the visit 
while being observed and display thermometer reading for the Investigator to confirm and record)  
 
8.[ADDRESS_638712]’s progress and perform /record  the following:  
 
• Numerical Rating Scale (NRS)  pain score – this pain survey must be administered prior to 
performing the other visit assessments to prevent information from these assessments biasing the 
subject’s responses.  
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, 21 SEP 2020   
      Page 21 of 37 
• New or updated adverse ev ents, if applicable . Adverse events must be reviewed and assessed by 
[CONTACT_737] . 
• Current work status  
• Review of concomitant medications  
• Current body temperature ( for telehealth visits, the patient will take their temperature during the visit 
while being observed and display thermometer reading for the Investigator to confirm and record)  
 
8.7 STUDY COMPLETION/DISCONTINUATION  
The Primary E ndpoints will be eval uated after all subjects reach their [ADDRESS_638713] baseline characteristics including , age, gender, BMI, and race/ethnicity will be 
recorded.  
 
PAST MEDICAL HISTORY  
At screening, each subject’s medical /surgical history  will be reviewed  with the subject and updated if needed. 
Once up to date, this medical/surgical history will be used as the basis for eligibility determination.  
 
PHYSICAL EXAMINATION  
A standard physical examination  will be conducted  according to the site’s  SOC , and eligibility criteria 
reviewed  to assess subject’s suitability for study participation.  The physical exam will include a review of 
vitals (temperature, blood pressure, pulse and respi[INVESTIGATOR_697]).  
 
PREGNANCY EVALUATION & TEST 
A pregnancy evaluation will be performed on female subjects  of childbearing  potential prior to procedure to 
ensure that the subject is not pregnant. Negative pregnancy status can be based on self -reported sexual 
history and contraception use. An in -clinic test must be performed using urine dipstick  testing when the 
subject  think s there is a potential that they might be pregnant.  
 
X-RAYS  
Subjects will have AP and lateral x -rays collected at the Screening Visit to rule out the possibility of a 
previous or existing tibial fracture. X-rays will also be ordered by [CONTACT_496803] a potentia l tibial fracture based on clinical exam and/or adverse event details 
provided by [CONTACT_423].  
 
NUMERICAL RATING SCALE - PAIN 
The Numerical Rating Scale (NRS) is a subjective measure in which individuals rate their pain on an eleven -
point numerical scale. The scale is composed of 0 (no pain at all) to 10 (worst imaginable pain). It has been 
shown that a composite scoring system i ncluding best, wors t, and current level of pain over the last [ADDRESS_638714]’s current wo rk status 
throughout the trial.   
 
10. EARLY DISCONTINUATION SUBJECTS  
10.[ADDRESS_638715] TO FOLLOW -UP (LTFU)  
Subjects who miss the final, 30-day study  follow -up will be regarded as Lost to Follow -Up. Site staff should 
perform and document a minimum of three attempts to cont act them via phone, and one attempt to reach 
them via certified mail to bring them in for the final study visit prior to considering the subject LTFU. The staff 
should document the date and type of attempted communication.  
 
All efforts should be made to ha ve subjects complete all follow -up visits but only subjects that miss the 30-
day follow -up will be considered LTFU.  
 
10.[ADDRESS_638716] may be withdrawn from the clinical investigation for reasons  including but not limited to the 
following :  
 
• Subjects may choose to withdraw from the clinical investigation under the terms of the Declaration of 
Helsinki and their consent documentation without having to give a reason;  
• Any adverse event which, in the opi[INVESTIGATOR_689], is related to the treatment and will 
endanger the well -being of the subject if treatment is continued;  
• Development of any intercurrent illness(es), infection or condition(s) that might interfere with the 
clinical investigation;  
• Non-compliance with the clinical investigation procedures deemed by [CONTACT_496804];  
• Any problem deemed by [CONTACT_496805].  
 
Regardless of the reason  for withdrawal, data available for the subject at the time of withdrawal, including the 
reason for withdrawal, will be documented  in the subject’s study records . The Investigator will treat all 
subjects discontinued from the investigation due to an adverse event until the event resolves. A subject that 
has been withdrawn from the study after treatment will not be replaced.  
 
10.[ADDRESS_638717]’s records.  
 
All subjects are free to withdraw from participation at any time, for an y reason, specified or unspecified, and 
without prejudice. However, if a subject expresses a desire to withdraw their consent for the study, the site 
should attempt to obtain written documentation for their study records.  
 
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, [ADDRESS_638718] notify them of their 
discontinuation from the study in writing.  
 
10.4 USE OF DATA FROM EARLY DISCONTINUATION CASES  
Study data collected previously for subjects who withdraw from the study, are discontinued from the study by 
[CONTACT_496806].  
 
10.5 ONGOING TREATMENT FOR EARLY DISCONTINUATION CASES  
Subjects who withdraw voluntarily or are discontinued by [CONTACT_496807].  
 
11. EARLY DISCONTINUATION: STUDY  
11.1 PROCEDURE FOR SUSPENSION OR EARLY TERMINATION  
The Sponsor may suspend or prematurely terminate this clinical investigation either at the investigational site 
An Investigator, IRB, or  regulatory authority may suspend or prematurely terminate participation in this 
clinical investigation at the investigational site for which they are responsible.  
 
If suspi[INVESTIGATOR_168343], or when so instructed 
by [CONTACT_100958], the Sponsor will suspend the clinical investigation while the risk is 
assessed. If an unacceptable risk is confirmed, the Sponsor will terminate the clinical investigation.  
 
The Sponsor will consi der terminating or temporarily suspending the participation of the investigational site 
or Investigator if monitoring or auditing identifies serious or repeated deviations on the part of an 
Investigator.  
 
If suspension or premature termination occurs, the terminating party will justify its decision in writing and 
promptly inform the other party . 
 
If suspension or premature termination occurs : 
 
The Sponsor will remain responsible for providing resources to fulfill the obligations from this protocol and 
existing agreements for following the subjects enrolled in the clinical investigation, and  the Investigator or 
authorized delegate  will promptly inform the enrolled subjects at his/her investigati onal site . 
 
If the study is terminated,  Active Life Scientific, Inc.  must comply with all applicable government regulations 
and the protocol -required subject follow -up. If discontinuation of the study should occur, the Investigator 
must return all clinical  investigation materials (including devices) to the Sponsor, and provide a written 
statement to the IRB explaining the reasons for the premature termination. All applicable clinical investigation 
documents shall be subject to the same retention policies, a s detailed in Section 19. 
 
11.2 PROCEDURE FOR RESUMING THE CLINICAL INVESTIGATION AFTER TEMPORARY 
SUSPENSION  
When the Sponsor concludes an analysis of the reason(s) for the suspension, implements the necessary 
corrective actions, and decides to lift the tempora ry suspension, the Sponsor will inform the relevant parties 
of the rationale and provide them with the relevant data supporting this decision.  Concurrence w ill be 
obtained from the IRB s and, where appropriate, regulatory authorities before the clinical inv estigation 
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, [ADDRESS_638719] been informed of the suspension, the Investigator or authorized delegate  will 
inform them of the reasons for resumption.  
 
11.3 ROUTINE CLOSE -OUT  
Routine close -out activities will be conducted to ensure that the Investigator' s records are complete, all 
documents needed for the Sponsor's files are retrieved, remaining clinical investigation materials are 
disposed of, previously identified issues have been resolved, and all parties are notified.  
 
12. PROTOCOL DEVIATIONS  
A protocol d eviation is an event whereby [CONTACT_496808] t the study 
according to the protocol . Conformance to the protocol is essential to the quality and integrity of the clinical 
study. Every effort should be made to avoid any deviation from the clinical protocol.  
 
Under emergency circum stances, deviations from the protocol  to protect the rights, safety and well -being of  
human subjects may proceed without prior ap proval of the Sponsor and the IRB . Such deviations shall be  
documented and re ported to the Sponsor within [ADDRESS_638720] of the study. After evaluation of each deviation, the Sponsor will determine if corrective and 
preventive actions need to occur.  
 
The Sponso r reserves the right to disqualify Investigator on the basis of repeated or serious deviations at their 
site. 
 
13. CONCOMITANT MEDICATIONS  
For the purposes of this clinical study, only current medications being taken or administered for the following 
will be recorded:  
 
• Pain (any type);  
• Inflammation (any type);  
• Muscle relaxation;  
• Numbness and/or tingling;  
• Hormonal replacement therapy ; and  
• Medications prescribed for treatment  of AEs/SAEs  
 
14. ADVERSE EVENT AND DEVICE DEFICIENCY REPORTING  
14.1 DEFINITIONS  
Device Deficien cy (DD) - A device deficiency is an inadequacy of a medical device with respect to its identity, 
quality, durability, reliability, safety or performance.  Device deficiencies include malfunctions, use errors, and 
inadequate labelling.   
 
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, 21 SEP 2020   
      Page 25 of 37 
Adverse Event (AE) – An adverse event is any untoward medical occurrence, disease, injury, or untoward 
clinical signs (including abnormal laboratory findings, surgical complications, etc.), whether related or 
unrelated to the investigational device or its use.   
 
Serious  Adverse Event (SAE)  – A Serious Adverse Event is an AE which:  
1. Led to a death,  
2. Led to serious deterioration in the health of the subject that either resulted in:  
a) A life -threatening illness or injury, or  
b) A permanent impairment of a body structure or a body function, or  
c) In-patient hospi[INVESTIGATOR_13266], or  
d) Medical or surgical intervention to prevent life threatening illness or injury or permanent 
impairment to a body structure or a body function.  
3. Led to fetal distress, fetal death or a congenital abnormality or birth defect (not anticipated in this 
study as pregnant women are excluded from the study).  
4. Other Serious (Important Medical Events)  
 
NOTE: Planned hospi[INVESTIGATOR_496792] -existing condition, without a serious deterioration in 
health, is not considered a serious adverse event.  
 
Unanticipated Adverse Device Effect (UADE)  – An Unanticipated Adverse Device Effect is:  
• Any serious adverse effect on health or safety o r any life threatening problem or death caused by, or 
associated with, a device, if that effect, problem, or death is not previously identified in nature, 
severity, or degree of incidence in th e IDE application ; or  
• Any other unanticipated serious problem associated with a device that relates to the rights, safety, or 
welfare of the subjects.  
 
14.2 CLASSIFICATION OF AN AE  
14.2.1  Severity  
The Investigator  will assess the severity of the AE and classify it according to the following definitions:  
 
MILD: Event/symptom is t ransient and well -tolerated by [CONTACT_423].  
MODERATE : Event/symptom causes discomfort and interferes with routine activities of the subject.  
SEVERE : Event/symptom interferes considerably with the routine activities of the subject or causes inability to 
work.  
 
These definitions are for descriptive purposes only and are independent of the judgment of whether an event 
is classified as an AE or an SAE.  
 
14.2.2  Relationship  
The relationship between the use of the medical device (including the medical pr ocedure) and the 
occurrence of each adverse event shall be assessed and categorized. During causality assessment, clinical 
judgment shall be used, and the Clinical Protocol shall be consulted, as all the foreseeable potential risks are 
listed here. The presence of conf ounding factors, such as concomitant medication/treatment, other 
concurrent illness or risk factors shall also be considered.  
 
The Investigator  will assess the potential relationship of the AE or SAE to the use of the investigational 
device /procedure  and classify the causality of the event according to the following definitions.  
 
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, 21 SEP 2020   
      Page 26 of 37 
DEFINITELY RELATED : An AE that has a strong causal relationship. An AE that follows a strong temporal 
relationship, follows a known response pattern, and cannot reasonably be expl ained by [CONTACT_26562]’s clinical state or other therapi[INVESTIGATOR_014].  
 
PROBABLY RELATED : An AE that potentially has a causal relationship. The AE has a reasonable temporal 
relationship and alternative etiology is less likely compared to the po tential relationship to the use of the 
investigational device /procedure . 
 
POSSIBLY RELATED : An AE that potentially has a causal relationship. The AE has a reasonable temporal 
relationship to the use of the investigational device /procedure  but alternative e tiology is equally likely 
compared to the potential relationship to the use of the investigational device /procedure .  
 
NOT RELATED : An AE without any apparent causal relationship. The AE is due to the underlying disease state 
or is due to concomitant medic ation or therapy not related to the use of the investigational device /procedure . 
 
UNKNOWN RELATIONSHIP : If the AE cannot be determined to have a causal relationship, it will be classified as 
unknown.  
 
NOTE: Where the Investigator or Sponsor remains uncerta in about how to classify the event, this should not 
cause them to exclude any possible relatedness , and the Investigator should consider classify ing the event 
as “Possibly Related”.  
 
14.[ADDRESS_638721] (including abnormal laboratory findings) whether  or 
not it is related to the investigational device. Any condition at baseline that is recorded as a preexisting 
condition is not an AE unless it wors ens in intensity or duration.  
 
The collection of AEs will begin in the exam  room  once the patient is enrolled , i.e. the Investigator delivers 
the local anesthetic . All AEs that occur through completion of the final follow -up visit  for each subject (day 
30), whether observed by [CONTACT_496809], and whether or not thought to be device -related, 
should be reported in detail and followed to resolution.   
 
The description of the AE will include the date and time of onset, severity, causal relationship to the 
investigational device, if any treatment was required, and the outcome of the event. Significant new 
information and updates should continue to be captu red in the subject’s records and in the EDC as they 
become available and the adverse event should be followed until it is resolved or no further improvement is 
expected, or the subject is lost to follow -up. 
 
14.3.[ADDRESS_638722] information below, the Sponsor should be notified of all SAEs within one (1) business day 
of the site becoming aware of the event  by [CONTACT_496810]. In the event the EDC is 
unavailable for any reason, notification to Active Life should  be made via email or phone as follows:  
 
Sponsor Contact : [CONTACT_496811]  
E-mail: [EMAIL_9496]  
Phone : +[PHONE_10323] x106  
 
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, [ADDRESS_638723] been met include forwarding a copy of the written, signed report that was s ent to the IRB 
to the Sponsor. Copi[INVESTIGATOR_496793]’s site files and the Sponsor’s Trial 
Master File . 
 
New SAEs will only be documented for each subject until the last study related subject visit  (day 30) .  
 
14.3.[ADDRESS_638724]. For AEs that are determined to be UADEs, the Sponsor will submit an expedited 
safety report to the FDA’s Center for Devices and Radiological Health (CDRH).  The expedited safety report 
will be submitted to the FDA  and governing IRB  as soon as possible and, in no event, later than ten (10) 
business days  after this is determined .  
 
If, follow ing receipt and investigation of follow -up information regarding an AE that was previously 
determined not to be a UADE, the Sponsor determines that the event does meet the requirements for 
expedited reporting, the Sponsor will notify the FDA as soon as pos sible, but in no event later than ten (10) 
business days  after this is determined.  
 
14.3.[ADDRESS_638725] (UADE)  
Active Life Scientific, Inc ., in consultation with the Investigators, shall determine if the reported  event 
presents an unreasonable risk to study subjects. If the event is determined to pose an unreasonable risk, the 
Sponsor may  terminate the investigation, or the parts of the investigation presenting that risk, within 5 
business days after Sponsor makes  an “unreasonable risk” determination or within [ADDRESS_638726] of 
Care until the event is resolved or no further clinical improvement is expected, or (if applicable) the subject  is 
LTFU . 
 
14.5 CLINICAL EVENTS COMMITTEE (CEC)  
An independent Clinical Events Committee (CEC) comprising of three physicians who are  familiar with the 
study indication will review and adjudicate all adverse events and protocol deviations  to remove 
Investigator -based bias in AE/PD classification and allow for the poolability of data.  The CEC will consist of 
physician(s)  who are not affi liated with the Sponsor and are not participating in the study.  The 
recommendations of the CEC override the Investigator ’s classification and become part of the clinical trial data 
set. 
 
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, 21 SEP 2020   
      Page 28 of 37 
The CEC will adjudicate all AEs and potentially reclassify the severi ty, seriousness, anticipatedness, and 
relationship to the device/procedure . The CEC will also adjudicate all PDs and potentially reclassify the 
deviations in terms of whether they are minor or major deviations .  
 
15.  SOURCE DOCUMENTATION  
The Investigator will be supplied with one physical binder per subject. The binder will contain paper Case 
Report Forms (CRFs)  for collection of study data. It is expected that these CRFs will be the source of all 
study data. It is possible that additional supplemental source may be captured once the study is underway, 
but the primary source of all study data is expected to be the paper CRFs . 
 
16. STUDY  MONITORING  
16.1 SITE MONITORING  
The study will be monitored to ensure that it is conducted in conformance with the monitoring plan by [CONTACT_496812] , recognized Good Clinical Practices, 
FDA’s IDE guidance documents, and federal regulations outlined in 21 CFR 812.43(d) and [ADDRESS_638727] to a quality assurance audit by [CONTACT_98224], as well as 
inspection by [CONTACT_4708]. It is important that the Investigator and relevant study 
personnel are available  during on -site monitoring visits or audits and that sufficient time is devoted to the 
process.  
 
The organization responsible for monitoring the study is:  
 
MCRA , LLC   
[ADDRESS_638728] NW, Suite 1000  
Washington DC [ZIP_CODE]  
 
In addition to ensuring adequate communication between the Investigators and the Sponsor, the CRO’s 
duties may include on -site visits and review of study documents and reported data  per the Clinical Monitoring 
Plan. The CRO study representatives will be pr ovided with appropriate device and protocol training prior to 
the study and will follow a Monitoring Plan for all study -related monitoring activities.  
 
16.2 MONITORING  ACTIVITIES  
On-site monitoring visits may include , but are not limited to  a pre -study Site Ini tiation Visit, periodic Interim 
Monitoring Visits, and a Close -Out Visit at the end of the site’s participation in the study.  
 
The Investigator will allocate adequate time for monitoring activities. The Investigator will also ensure that the 
monitor or oth er compliance or quality assurance reviewer is given access to the study -related documents 
and study -related facilities and  has adequate space to conduct the monitoring visit.  
 
Monitoring visits will be documented on monitoring visit reports . On-site and r emote monitoring will aim to 
verify that:  
 
• Compliance with the clinical protocol and applicable regulations is being maintained  
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, 21 SEP 2020   
      Page 29 of 37 
• Source data is verified and signed -off upon as accurate  
• Subject files are accurate and complete  
• Subject withdrawal has been doc umented (if applicable)  
• Subject non -compliance has been documented (if applicable)  
• The Investigator and site staff are informed and knowledgeable of all relevant document updates 
concerning the clinical investigation  
• Only authorized individuals are perform ing study -related functions  
• The investigational device is being used according to the protocol and instructions for use  
• Adequacy of staffing and facilities  
• Signed and dated ICFs have been obtained from each subject  
• CRFs and queries are complete  
• All adverse  events are reported to the Sponsor  
• All serious and unanticipated adverse device events are reported to the Sponsor and the IRB  
• All other required IRB reports, notifications, applications, submissions, and correspondence are 
maintained in the Investigator’s files and are accurate  
• Corrective and preventive actions have been implemented (if applicable)  
 
16.[ADDRESS_638729] frequency of visits shall be determined shall depend upon factors  such as but not limited to the 
following :  
 
• Rate of subject enrollment  
• Experience of the I nvestigator in conducting clinical studies  
• Record of previous site compliance  
 
17. AUDITS AND INSPECTIONS  
Participation as an Investigator in this study implies acceptance of potential inspection by [CONTACT_316130]. The Investigator must also be prepared to permit study -related audits and inspections 
by [CONTACT_1034], CRO, IRB and the site’s in stitutional compliance and quality assurance groups. The 
Investigator will ensure the capability for inspections of applicable study -related facilities, records and 
reports.  
 
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, 21 SEP 2020   
      Page 30 of 37 
18. STATISTICAL ANALYSIS PLAN  
18.1 STUDY HYPOTHESIS  
The primary hypothesis is that the pro bability of experiencing device -related  Serious Adverse Events (SAE) 
for subjects treated with the investigational device is smaller than the performance goal of 1%. Formally, that 
hypothesis to be tested are:  
H0:  The expected proportion of subject s with device -related SAE up to Day 30 (p T) is greater than or 
equal to the performance goal (PG) of 1.0%.  
HA:  The expected proportion of subject s with device -related SAE up to Day 30 (p T) is less than the 
performance goal (PG) of 1.0%.  
These hypotheses may be s ymbolically represented as:  
H0: pT ≥ PG = 1.0%  
Ha: pT < PG = 1.0%  
Where p T is the device -related  SAE rate for subjects treated with the investigational device.  
If the Bayesian Posterior Probability that  pT < PG is greater than or equal to .975, the alternative hypothesis 
will be accepted, and it will be concluded that the device meets the performance goal.  
18.2 SAMPLE SIZE ANALYSIS  
A review was performed on all the published and unpublished clinical data on the OsteoProbe device. In 
order to systematically review and identify potential data sources for the informative prior initial criteria was 
established. In order for the data to be included as an informative prior the following criteria needed to be 
met:  
 
1. a minimum of 30 days follow -up on patients ; 
2. the OsteoProbe procedure was administered in a manner consistent with the IDE;  
3. the data commented on safety around serious adverse events.  
 
First, a total of 40 published  articles were reviewed . Of the published lit erature , and four published studies 
met criteria “ 1” (Patient Follow -up) and “ 2” (OsteoProbe Procedure) outlined in Section 2, above . The 
following are the four literature articles:  
(1) Sundh D, et al. [JBMR. 2018;33(7):1242 -1251],  
(2) Pérez -Sáez MJ et al. [Bone.  2018;116:290 -294],  
(3) Robert Guerri -Fernandez, et al [AIDS 2018, 32:913 –920], and  
(4) Mellibovsky L, et al. [JBMR 2015;30(9):1651 -1656].  
  
However, two (Sundh et al and Pérez -Sáez et al) of the four did not explicitly state the safety outcomes in 
the study. Given the articles did not explicitly state the safety result, the two articles were excluded from the 
informative prior.  Only two studies met all three criteria, Robert Guerri -Fernandez et al and Mellibovsky L et 
al.  
  
Table 6. Literature Data Evaluation  
Study  Criterion 1: >30 
day follow up  Criterion 2: 
Procedure with 
OsteoProbe  Criterion 3: 
Language 
explicitly Informative 
Prior Inclusion  
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, 21 SEP 2020   
      Page 31 of 37 
stating safety 
results  
Sundh D, et al  X X  No 
Pérez -Sáez MJ et al  X X  No 
Robert Guerri -Fernandez, et 
al X X X Yes 
Mellibovsky L, et al  X X X Yes 
 
Additionally, a review was performed on all unpublished and ongoing studies with the OsteoProbe device. 
The same criteria were applied in evaluation of these potential datasets. A total one  unpublished or two 
ongoing studies  were found  meet the three criteria for inclusion as an informative prior. The table below 
summarizes the evaluation and inclusion of this information. Each of the included clinical data is further 
summarized below.   
 
Table 7. Unpublished or Ongoing Clinical Data Evaluation  
Study  Criterion 1: >30 
day follow up  Criterion 2: 
Procedure with 
OsteoProbe  Criterion 3: 
Language 
explicitly 
stating safety 
results  Informative 
Prior Inclusion  
OHSU (unpublished)  X X X Yes 
LUMC (ongoing)  X X X Yes 
BARWON (ongoing)  X X X Yes 
 
The summary findings are shown below Table 8.  
Table 8: Informative Prior Data  
Study  # Subjects  Device 
Related SAEs  
Robert  Guerri -Fernandez  (2018)  40 0 
Mellibovsky  L, et al (2015)  52 0 
OHSU  18 0 
LUMC  (ongoing)  110* 0* 
BARWON  (ongoing)  50* 0* 
Total  270*  0* 
  *Anticipated at the time of De Novo submission  
 
These five studies contain  or will contain  270 subjects with an anticipated rate of zero subjects experiencing 
a device -related Serious adverse events.  Given there is no variability between these studies, the data are 
pooled together and collectively constitute the informati ve prior.  To be conservative, the initial assumption 
will only consider 215 subjects with zero device -related adverse events.  The informative prior was 
constructed as Jeffries prior plus the data in  Table 8, that is, Beta(.5 + data, .5 + data).   
When there are zero device -related  SAEs in [ADDRESS_638730] been shown to meet the performance goal. Therefore, only if there are zero device -
related  SAE’s will the alternative hypoth esis be accepted.  
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, 21 SEP 2020   
      Page 32 of 37 
18.3 STUDY POPULATIONS  
18.3.1  Primary Analysis Set 
All subjects with a time of procedure start recorded will be included in the Primary Analysis Set. The Primary 
Analysis Set will be utilized in testing of the primary safety endpoint.  
18.3.2  Per Protocol Analysis Set  
A per protocol (PP) analysis may be performed excluding enrolled subjects that are subsequently found to 
not meet the inclusion or exclusion criteria based objective criteria or that experience an intercurrent event 
during follow -up that makes the device -related  SAE endpoint uninterpretable .  
18.3.3  Training Cases  
There are no training cases for this protocol.  
18.4 TESTING OF PRIMARY SAFETY  HYPOTHESES  
The primary safety hypothesis will be tested by [CONTACT_496813] -related  SAE rate is less (i.e., better) than the performance goal. The Bayesian posterior probability 
will be calculated by [CONTACT_496814]. The Bayesian posterior probability 
will be calculated through nu merical integration with regards to the performance goal of .01. When the 
Bayesian posterior probability of the conditional device -related  SAE rate is higher than .975, the alternative 
hypothesis will be accepted, and it will be concluded that the device h as met the specified performance goal 
of 1%. As stated above, this will only occur when there are zero out of 40 events.  
Supporting analyses will summarize the Bayesian posterior probabilities that the device -related SAE rate is 
lower than varying referenc e margins.  
95% credible intervals of the device -related  SAE rate will also be reported without using an informative prior 
distribution.  
18.5 MISSING DATA/SENSITIVITY ANALYSIS  
Given the short follow -up, there is not expected to be a large amount of missing data . Detailed descriptions 
of the reason(s) for missingness will be provided for every missing subject and timepoint. Subjects missing 
data will be multiply imputed using the posterior distribution of the observed data only. Bayesian posterior 
summarizes will  characterize best - and worst -case scenarios as sensitivity to MAR assumption necessary for 
the imputation model. There will be no imputation for secondary effectiveness endpoints.  
 
18.6 SECONDARY EFFECTIVENESS ENDPOINTS  
The secondary endpoints of this study, following evaluation with the OsteoProbe System, are:  
• Follow -up NRS Pain scores take at Procedure, 1 -day, and 7 -day follow up visits  
• BMSi  scores at Procedure  
• Adverse event through day 30.  
• All device -related adverse events through day 30.  
• Serious adverse ev ents through day 30; and  
• Unanticipated adverse device effects (UADE) through day 30.  
Secondary endpoints are described in the Clinical Protocol. Continuous variables will be described by [CONTACT_496815], the number of missing observations, means , standard deviations, medians, 
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, 21 SEP 2020   
      Page 33 of 37 
minimums, and maximum. Responder variables will be described by [CONTACT_46932], the number 
of missing observations, and percentages.  Secondary endpoints may be further described through credible 
intervals or othe r posterior distribution summaries.  
18.7 SAFETY ANALYSES  
Assessment of the safety of the investigational device will include an evaluation of the incidence and severity 
of complications and adverse reactions associated with the treatment.  
Adverse event rates will be summarized by [CONTACT_496816]: 1) per subject 
incidence of specific AEs and classes of AEs and 2) by [CONTACT_15992], summarizing event counts by [CONTACT_496817] (CDRH 2004).1 device-related  events will be summarized 
by [CONTACT_229122].  
Event listings that include details such as relatedness, severity, onset, and resolution status will be provided 
for all events and relevant subsets of events such as serious events and r elated events. Safety evaluations 
will be performed using the Primary Analysis Set.  
The summary tables will show the adverse events (in coded terms), the total number of events, and the 
number and the percentage of subjects affected (“subject wise evaluati on”) and stratified by [CONTACT_496818]. Data of dropouts will not be presented separately, but possible bias will be 
discussed in the final report.  
All AEs will be summarized in listings for the Primary Analysis Set. The follow ing AE listings will be provided:  
1. AE Listing [ADDRESS_638731]  
3. AE Listing 3 Serious AEs  
4. AE Listing 4 Severe AEs  
5. AE Listing 5 Device -related  AEs 
6. AE Listing 6 Serious device -related  AEs 
7. AE Listing 8 Other A Es 
8. AE Listing 9 AEs among subjects discontinued early  
9. AE Listing 10 AEs among subjects who died  
18.8 EVALULATION OF POOLABITIY  
Descriptive summarizes of the selected secondary endpoints will be provided stratifying by [CONTACT_496819] o rder to provide evidence that justifies poolability. Clinically relevant baseline variables 
include:  
• Age category (>=50 vs < 50 years old)  
• Sex 
• Site 
18.9 CHANGES TO THE STATISTICAL ANALYSIS PLAN  
Any changes to the statistical analysis plan will be fully documen ted in the Clinical Study Report.  
 
1 CDRH. Guidance for Industry and FDA Staff: Clinical Data Presentations for Orthopedic Device 
Applications, December 2, 2004.  
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, 21 SEP 2020   
      Page 34 of 37 
18.10  SOFTWARE  
All statistical analyses will be performed with SAS version 9. 4 or above software (SAS Institute Inc., Cary, 
North Carolina)  or R version 3.6.3 or above (The R Foundation for Statistical Computing Platform) . 
 
19. REGULATORY CONSIDERATIONS AND ETHICAL REVIEW  
19.[ADDRESS_638732] . In addition, the Sponsor will keep the regulatory 
authorities informed of any UADEs  throughout the study course, if applicable.  
 
19.2 REGULATORY CONSIDERATIONS  
This study will be conducted in accordance with the Good Clinical Practice (GCP) guidelines and other 
applicable regulatory requirements including , but not limited to:  
 
• FDA Regulations on Investigational Device  Exemption (21 CFR 812)  
• FDA Regulations on research with human subjects  (21 CF R 50, 54 and 56)  
• Health and Human Services (DHHS) Regulations on research with human subjects  (45 CFR 46 
Subparts A, B, C, and D)  
• E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1) Guidance for Industry  
• The Declaration of Helsinki  
 
19.[ADDRESS_638733] study -related injury 
according to local regulation requirements.  
 
 
20. DATA HANDLING AND REC ORDKEEPI[INVESTIGATOR_1645]  
20.1 DATA MANAGEMENT  
All required data for this study will be collected on standardized eCRFs. The Investigator or  investigational 
site will maintain, at the investigational site, in original format, all essential study  documents and source 
documentation that support the data collected on the study subjects in  compliance with International 
Conference on Harmonization (ICH)/Good Clinical Practice (GCP)  and any local regulatory guidelines.  
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, 21 SEP 2020   
      Page 35 of 37 
 
eCRFs will be completed in a 21 CFR Part 11 compliant electronic data capture (EDC) system for each 
subject  enrolled into the clinical study. The Investigator or delegated site staff  will enter t he source data into 
the eCRFs and study  monitors will perform a source document verification process . 
 
The Investig ator will be responsible for the review and sign off on the Eligibility C riteria, Adverse Event, 
Protocol Deviation and Study Completion eCRFs and will sign each subject ’s casebook once the subject  
completes the study to attest that all data entered on the  eCRFs are complete and accurate. All of the above 
signatures will be completed digitally within the EDC system using the system’s Part 11 compliant digital 
signature [CONTACT_496825].  
 
Any required data clarifications will be handled within the EDC system’s query management system.  The 
EDC will be programmed to automatically place data clarification queries on missing values and values out 
of acceptable ranges. Study monitors and data managers will also be able to add data clarification queries to 
data points within the system. Study coordinators will have the opportunity to correct data and/or respond to 
the query for review by [CONTACT_496820].  
 
All procedures for the handling and analysis of data will be conducted using good clinical data  management 
practices within systems meeting FDA guidelines for the handling, storage, and analysis of data for clinical 
studie s. 
 
The CRO study representatives will follow a Data Management Plan for all study -related data  
management activities.  
20.[ADDRESS_638734] KEE PI[INVESTIGATOR_496794], complete, and current records relating to participation 
in this clinical investigation. If the Investigator wishes to assign the responsibility of maintaining the study files 
to someone else or move them to another location, he/she should consult with the study sponsor in writing 
regarding the change. The Investigator will take measures to ensure that these essential documents are not 
accidentally damaged or destroyed. If for any reason the Inves tigator withdraws responsibility for maintaining 
these essential documents, custody must be transferred to an individual who will assume responsibility and 
the Sponsor must receive written notification of this custodial change.  
 
 
The sponsor and Investiga tors will retain the specified records and reports for up to two years after the 
marketing application is approved for the investigational device; or, if a marketing application is not submitted 
or approved for the investigational device, until two years a fter investigations under the IDE have been 
discontinued and the FDA so notified.  
 
The Investigator and Sponsor will maintain records in accordance with 21 CFR 812, Subpart G, to include:  
 
• Current and past versions of the IRB -approved clinical protocol an d amendments and corresponding 
IRB-approved consent form(s) and, if applicable, subject recruitment advertisements  
• FDA correspondence related to the IDE application; including supplemental IDE applications, current 
Investigator  lists, progress reports  
• IRB correspondence (including submissions and approval notifications) including safety and protocol 
deviation reports, and annual or interim reports  
• Signed Clinical Trial Agreement  
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, 21 SEP 2020   
      Page 36 of 37 
• Signed Investigator Agreements and financial disclosure forms for  the participating Investigator  
• Curriculum vitae (Investigator and Sub -Investigators)  
• Certificates of required training for the Investigator and  any Sub-Investigators, including human 
subject protection and Good Clinical Practice  
• Instructions for handling the investigational device and other study -related materials  
• Device tracking logs  
• Signed ICFs  
• eCRF and Source Documents  
• Monitoring visit confirmation and follow -up letters  
• Copi[INVESTIGATOR_496795] -Investigator correspondence, including notifications of adv erse event 
information  
• Screening and Enrollment Log  
• Signed informed consent forms  
• Final clinical study report  
 
20.[ADDRESS_638735] identification code (two digit site 
identification number and three digit subject name [CONTACT_496826]) will be 
used that allows identification of  all data reported for each subject without traceability back to the actual 
subject.  
 
The Investigator shall provide direct access to source data during and after the clinical investigati on for 
monitoring, auditing, IRB review and regulatory authority insp ections.  
 
“Protected Health Information” will be treated and maintained in compliance with the Health Insurance 
Portability and Accountability Act of 1996 (HIPAA) Privacy rule.  
 
The duration of storage time of personal data at the investigational site wi ll be in accordance w ith national 
regulations  (see section 1 9.2). 
 
Information obtained in the course of executing this study may be presented for regulatory, clinical or 
educational purposes as long as no subject is identified. The data collected is the p roperty of Active Life 
Scientific, Inc.  
 
20.[ADDRESS_638736] of this study is intended  be used to support an application by [CONTACT_496821], Inc.  as a de novo submission for  FDA. Publication of the results of the study will follow Active Life 
Scientific, Inc. ’s Publication and Presentation Policy.   
 
The study will be registered on Clinicaltrials.gov in compliance with 42 CFR Part 11. Results of the study, 
including an unantic ipated early termination of the study, will be posted to the Clinicaltrials.gov database at 
Clinical Study Protocol  
 
 
 
Active Life Scientific, Inc. OP2020    CONFIDENTIAL             Version 4.0, 21 SEP 2020   
      Page 37 of 37 
the conclusion of the study. In the event that the study is terminated early, the posting of these results will be 
completed within 30 days of completion of data an alysis.  
 
 
20.5 INVESTIGATOR REPORTS  
The Investigator  is responsible for the timely preparation and submission of the reports cited below.  
 
Table 9: Investigator Reports  
Report  Sent To  Timing of Report  
Unanticipated 
adverse device 
effect (UADE)  Active Life 
Scientific , IRB  UADE must be reported as soon as possible, but in no 
event later than [ADDRESS_638737] yearly  
Deviations 
from the 
investigation al 
plan Active Life 
Scientific , IRB 
(FDA)  A deviation to protect the life or physical well -being of a 
subject in an emergency must be reported  as soon as 
possible but  no later than [ADDRESS_638738] (and are not an 
emergency) must receive prior approval by [CONTACT_496822].  
Device use 
without 
informed 
consent  Active Life 
Scientific , IRB  This deviation must be reported within [ADDRESS_638739] be submitted within 3 months after 
termination or completion of the investigation or the 
Investigator ’s part of the investigation.  
Other  FDA, IRB  Upon request, accurate, complete, and current 
information about any aspect of the investigat ion must 
be reported.  
   
 